Industrial enzymes: Cycles
Steady growth, with dips when energy costs spike
What this tab covers How its prices and margins move: past booms and busts with price levels, the spread or margin that the industry watches, the drivers of the cycle and the metrics to track.Enzymes are not a price-cyclical commodity. Prices are set by contract and value in use, and are not public. The cycle shows up in volumes and margins: US ethanol output and the farm economy drive bioenergy sales; detergent reformulation drives household care; livestock disease drives feed. Leaders have kept steady mid-single-digit organic growth and high margins, with dips when energy and raw material costs spike, as in 2022 (indicative). Novonesis grew 7% organically in 2025 and guided 5-7% for 2026.
The spread to watch No product spread; leaders' gross and EBITDA marginsNovonesis adjusted gross margin 59.1% and adjusted EBITDA margin 37.1% in 2025 (Novonesis Annual Report 2025).
Booms and busts
- 2008-2009
Financial crisis and US ethanol plant bankruptcies hit bioenergy enzyme sales (indicative).
not public; company sales growth slowed (indicative)
- 2022
Energy, sugar and logistics cost inflation squeezed margins; producers raised prices (indicative).
not public
- 2024-2026
Novozymes and Chr. Hansen merged into Novonesis; 2025 organic growth 7%, Q4 4%; Food & Health 8%, Planetary Health 6%.
adjusted EBITDA margin 37.1% (2025), guided 37-38% for 2026 (Novonesis)
What drives the cycle
- Ethanol output. Grain ethanol in the US, Brazil and India uses amylases and glucoamylases.
- Detergent reformulation. Cold-wash and compaction trends raise enzyme dosing.
- Livestock output and phosphate prices. Dear phosphate makes phytase more valuable.
- Biotech advances. New strains and enzymes create new uses and protect margins.
Metrics to track
| Metric | Why it matters | Where to track it |
|---|---|---|
| Novonesis organic sales growth by segment | Best public read of the industry | Novonesis quarterly reports |
| US ethanol production | Bioenergy enzyme volumes | US EIA |
| Advanced Enzyme Technologies results | Indian market read | BSE/NSE filings |